NEUP vs BIIB vs KO

For growth investors, The Coca-Cola Company (KO) is the stronger pick with 1.

9% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Biogen Inc. (BIIB) offers the better valuation at 22. 3x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Biogen Inc. (BIIB) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Biogen Inc.

(BIIB) is the cheapest at 22. 3x versus The Coca-Cola Company at 26. 1x. On forward P/E, Biogen Inc. is actually cheaper at 13. 5x.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

3%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: KO returned +115. 0% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Neuphoria Therapeutics Inc. 's 1. 38β — meaning NEUP is approximately -693% more volatile than KO relative to the S&P 500. On balance sheet safety, Neuphoria Therapeutics Inc. (NEUP) carries a lower debt/equity ratio of 1% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Coca-Cola Company (KO) is pulling ahead at 1.

9% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 5x forward P/E versus 24. 3x for The Coca-Cola Company — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIIB: 11. 1% to $218. 32.

In this comparison, KO (2.

6% yield) pays a dividend. NEUP, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, NEUP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEUP (Healthcare) and BIIB (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while NEUP, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.